摘要
目的:分析血清miR-21在肝癌发生过程中的表达水平并将其与传统肝癌血清标志物甲胎蛋白(AFP)比较,探索其成为肝癌早期诊断血清标志物的可能性。方法:二乙基亚硝胺(DENA)腹腔注射诱导建立大鼠肝癌模型,建模过程中收集造癌各个阶段的血清。Realtime-PCR检测血清miR-21的表达情况,ELISA法检测血清AFP水平。结果:与正常组及纤维化期大鼠相比,miR-21在肝硬化期、肝癌早期、肝癌晚期的大鼠血清均有不同程度上调(P<0.05),AFP在肝癌早、晚期的大鼠血清明显上调(P<0.05);与肝硬化期大鼠比较,肝癌早、晚期大鼠体内的miR-21表达显著上调(P<0.05),AFP在肝癌早期、肝癌晚期均显著上调(P<0.05)。结论:血清miR-21参与了肝癌发生的过程,对于肝癌发生的各个阶段均有很大的指示作用,可能作为肝癌预防和早期诊断的一个潜在标志物。
Objective： To investigate whether serum microRNA-21 （miR：21） could be used as a novel biomarker of liver cancer by comparing with serum AFP. Methods： Diethylnirtosamine （DENA） abdominal injection was applied to induce liver cancer in F344 rats. Blood samples of rats were collected for analysis. Real-time quantitative PCR technique and ELISA test were used respectively to measure the expressions of serum miR-21 and AFP during the liver cancer developing process. Results： Comparing with that in normal rats and liver fibrosis rats, miR-21 had higher expressions in liver cirrhosis rats, early liver cancer rats and advanced liver cancer rats （P〈0.05）, while AFP had higher expressions only in early and advanced liver cancer rats （P〈0.05）. During the developmental process of liver cancer, the miR-21 expression kept on increasing, while the AFP expression only increased at the stage of tumor formation. Conclusion： Data indicated that MiR-21 played an important role in liver cancer development and had diagnostic value for indicating early liver cancer.
出处
《现代生物医学进展》
CAS
2012年第12期2282-2284,2297,共4页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(81030010
81170419)
